Northwestern Mutual Wealth Management Co. Lowers Stock Holdings in Pfizer Inc. $PFE

Northwestern Mutual Wealth Management Co. lessened its stake in Pfizer Inc. (NYSE:PFE) by 8.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 668,687 shares of the biopharmaceutical company’s stock after selling 60,725 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Pfizer were worth $16,209,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in PFE. Clarkston Capital Partners LLC raised its stake in shares of Pfizer by 22.5% during the second quarter. Clarkston Capital Partners LLC now owns 81,688 shares of the biopharmaceutical company’s stock worth $1,980,000 after purchasing an additional 15,000 shares during the last quarter. Johnson Financial Group Inc. increased its stake in Pfizer by 40.5% in the 2nd quarter. Johnson Financial Group Inc. now owns 121,497 shares of the biopharmaceutical company’s stock valued at $2,945,000 after buying an additional 35,003 shares during the period. Korea Investment CORP raised its position in Pfizer by 20.6% during the 2nd quarter. Korea Investment CORP now owns 4,487,561 shares of the biopharmaceutical company’s stock worth $108,778,000 after buying an additional 767,323 shares during the last quarter. Sumitomo Mitsui Financial Group Inc. lifted its stake in shares of Pfizer by 10.1% in the 2nd quarter. Sumitomo Mitsui Financial Group Inc. now owns 124,200 shares of the biopharmaceutical company’s stock worth $3,011,000 after acquiring an additional 11,345 shares during the period. Finally, Elevation Point Wealth Partners LLC boosted its holdings in shares of Pfizer by 15.8% in the second quarter. Elevation Point Wealth Partners LLC now owns 19,458 shares of the biopharmaceutical company’s stock valued at $472,000 after acquiring an additional 2,649 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.2%

PFE opened at $25.76 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market cap of $146.46 billion, a price-to-earnings ratio of 13.70, a PEG ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The business’s fifty day moving average is $25.01 and its two-hundred day moving average is $24.60.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s payout ratio is presently 100.00%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on PFE shares. UBS Group restated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Morgan Stanley decreased their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Sanford C. Bernstein reissued a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. Finally, Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.39.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.